Bolte Axel 4
4 · Inozyme Pharma, Inc. · Filed Jun 20, 2024
Insider Transaction Report
Form 4
Bolte Axel
Director
Transactions
- Award
Stock Option (right to buy)
2024-06-18+28,000→ 28,000 totalExercise: $4.40Exp: 2034-06-17→ Common Stock (28,000 underlying)
Footnotes (1)
- [F1]The option was granted on June 18, 2024. The shares underlying the option are scheduled to vest as to 100% of the shares on June 18, 2025, or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date.